Advances in therapeutic nano-drug delivery systems in infectious lung diseases: a review

General Medical Research, Epidemiology*
This is not the most recent version. There is anewer versionof this content available.
Preprint
3.5

Gang Sheng# Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, 101149, China++Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

Na Tian# Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, 101149, China++Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

Huijuan Duan Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, 101149, China++Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

Zhaogang Sun* Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, 101149, China++Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

Hongqian Chu* Translational Medicine Center, Beijing Chest Hospital, Capital Medical University, 101149, China++Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

# contributed equally to this work


Abstract

Infectious lung diseases are primary or secondary lung inflammatory diseases caused by infectious agents such as bacteria, viruses, or fungi. Oral or intravenous administration of antibiotics is the most common treatment method, but some drugs suffer from poor release stability, high systemic toxicity, and induction of drug resistance. Nano drug delivery systems (DDS) are promising alternatives for the treatment of pulmonary infectious diseases, with particular advantage in enhancing drug delivery stability and solubility, improving pulmonary accumulation, reducing systemic toxicity, and combating drug resistance. This review provides a brief overview of the mechanisms and classification of pulmonary infectious diseases, outline new approaches and ideas for representative pulmonary drug delivery methods in recent years, and briefly summarized the toxicity of the present pulmonary nano-drug delivery systems. We believe that nano-based therapeutic strategies will provide great potential to broaden the scope of treatment of infectious lung diseases and enhance the therapeutic efficacy.

Comments
Send
Version History
  • 31 Aug 2022 10:12 Version 1
Rapid Rating
Your professional field is different from the direction of this article
Settings
  • Is the publication of relevance for the academic community and does it provide important insights? Is the language correct and easy to understand for an academic in the field? Are the figures well displayed and captions properly described? Is the article systematically and logically organized?
    Level of Quality
    0.0
  • Is the hypothesis clearly formulated? Is the argumentation stringent? Are the data sound, well-controlled and statistically significant? Is the interpretation balanced and supported by the data? Are appropriate and state-of-the-art methods used?
    Level of Repeatability
    0.0
  • Does the work represent a novel approach or new findings in comparison with other publications in the field?
    Level of Innovation
    0.0
  • Does the work have potential huge impact to the related research area?
    Level of Impact
    0.0
Submit

我们使用 cookie 将您与其他用户区分开来, 并在我们的网站上为您提供更好的体验。

关闭此消息以接受 cookie 或了解如何管理您的 cookie 设置。

了解更多关于我们的隐私声明..

goTop